Benzinga’s Top Ratings Upgrades, Downgrades For September 12, 2023
Upgrades RBC Capital upgraded the previous rating for Equinox Gold Corp (AMEX:EQX) from Underperform to Sector Perform. In…
Tesla Analyst With $24 Price Target Blasts Morgan Stanley’s $400 Target: ‘Where Is The Tech?’
Gordon Johnson, founder and CEO at GLJ Research, called into question on Monday the optimistic analysis of Morgan Stanley's Adam Jonas on Tesla Inc
Benzinga’s Top Ratings Upgrades, Downgrades For September 11, 2023
Upgrades Bernstein upgraded the previous rating for Brown-Forman Corp (NYSE:BF) from Market Perform to Outperform. For Nu Holdings…
Tesla Stock To $400? Morgan Stanley’s Jonas Boosts Price Target By 60% To Wall Street High On Dojo’s $500B Potential
Jonas has upgraded his rating on Tesla from 'equal-weight' to 'overweight,' boosting the price target by 60% to $400.
Healthcare Focused REIT Omega Healthcare’s De-Risked Portfolio Attracts Investors Amidst Uncertain Environment
Mizuho Securities has upgraded Omega Healthcare Investors Inc (NYSE: OHI) from Neutral to Buy with a price target of $35, up from $31, citing optimistic industry and
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hem
Benzinga’s Top Ratings Upgrades, Downgrades For September 8, 2023
Upgrades Wells Fargo upgraded the previous rating for TC Energy Corp (NYSE:TRP) from Underweight to Equal-Weight. TC Energy…
Why This Adobe Analyst Is Turning Bullish Ahead Of Q3 Earnings
Shares of Adobe Inc (NASDAQ: ADBE) have been in focus ahead of the company’s fiscal third-quarter earnings release.
Benzinga’s Top Ratings Upgrades, Downgrades For September 7, 2023
Upgrades For Tri Pointe Homes Inc (NYSE:TPH), Oppenheimer upgraded the previous rating of Perform to Outperform. For the…
Sleep Device Player ResMed’s Potential Obstacles: Analyst Weighs Obesity Drugs & Philips’ Re-Entry
Needham upgraded ResMed Inc (NYSE: RMD) from a Hold to Buy rating with a price target of $180